PDS Biotechnology (NASDAQ:PDSB) Stock Rating Reaffirmed by HC Wainwright

PDS Biotechnology (NASDAQ:PDSB – Get Rating)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $21.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 170.62% from the company’s current price.

Several other research firms also recently commented on PDSB. Noble Financial raised their price objective on PDS Biotechnology to $19.00 in a research note on Monday, November 28th. B. Riley lifted their target price on PDS Biotechnology from $10.00 to $12.00 in a research report on Wednesday, December 28th. Finally, Chardan Capital boosted their target price on PDS Biotechnology from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, November 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.80.

PDS Biotechnology Trading Up 1.4 %

NASDAQ PDSB opened at $7.76 on Tuesday. The company has a quick ratio of 15.37, a current ratio of 15.37 and a debt-to-equity ratio of 0.49. The stock’s 50 day moving average is $9.49 and its 200 day moving average is $7.02. PDS Biotechnology has a twelve month low of $2.89 and a twelve month high of $13.65. The firm has a market capitalization of $220.85 million, a PE ratio of -7.68 and a beta of 2.23.

Institutional Trading of PDS Biotechnology

Several hedge funds have recently modified their holdings of the stock. Freedom Wealth Alliance LLC purchased a new position in shares of PDS Biotechnology during the fourth quarter worth about $29,000. Commonwealth Equity Services LLC raised its position in shares of PDS Biotechnology by 4.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 60,900 shares of the company’s stock worth $180,000 after purchasing an additional 2,440 shares during the last quarter. State Street Corp grew its stake in PDS Biotechnology by 5.6% in the 1st quarter. State Street Corp now owns 76,533 shares of the company’s stock worth $474,000 after acquiring an additional 4,057 shares during the period. BlackRock Inc. grew its stake in PDS Biotechnology by 1.0% in the 1st quarter. BlackRock Inc. now owns 435,604 shares of the company’s stock worth $2,697,000 after acquiring an additional 4,199 shares during the period. Finally, Knightsbridge Asset Management LLC grew its stake in PDS Biotechnology by 14.7% in the 4th quarter. Knightsbridge Asset Management LLC now owns 50,374 shares of the company’s stock worth $665,000 after acquiring an additional 6,458 shares during the period. 18.21% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

(Get Rating)

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.